CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial

Gut

Volumn 53, Issue 10, 2004, Pages 1485-1493

  Sandborn, W J ^a,b   Feagan, B G ^c   Radford Smith, G ^d   Kovacs, A ^e   Enns, R ^f   Innes, A ^g   Patel, J ^g  

^a MAYO CLINIC   (United States)

^b Maya Clinic   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Rayal Brisbane Haspital ^*  (Australia)

^e Peterfy Hospital   (Hungary)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROHN DISEASE; DERMATITIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TUBERCULOSIS; UTERINE CERVIX CANCER; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4644325814     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.035253     Document Type: Article

References (18)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
2. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. Present DH, Rutgeerts, P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
5. Sands B, Van Deventer S, Bernstein C, et al. Long-term treament of fistulizing Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002;122:A81.
6. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
7. Farrell RJ, Alsahli M, Jeen YTJ, et al. Intravenous hydrocortisone premedication to prevent antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24.
8. Hanauer S, Rutgeerts P, Targan S, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology 1999;116:A731.
9. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243-6.
10. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-74.
11. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-4.
12. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-8.
13. Feagan BG, Sandborn WJ, Baker J, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000;118:A655.
14. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
15. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
16. Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996;49:1177-85.
17. Celltech announces results from CDP571 Phase III studies in Crohn's disease. Internet Press Release, 2002.
18. Hanauer S, Present D, Targan SR, et al. CDP571, a humanized monoclonal antibody to TNF-α, is well tolerated in Crohn's disease patients with previous hypersensitivity to infliximab. Digestive Disease Week, Orlando, FL, USA, 2003: abstract T, 1357.